lev-1 Antibody
Description
Target Overview
LYVE-1 is a CD44 homolog involved in hyaluronan transport and lymphatic vessel formation. Its expression is restricted to lymphatic endothelium, making it a key marker for distinguishing lymphatic from blood vessels .
Immunohistochemistry (IHC)
-
Human Tonsil: LYVE-1 antibody (15 µg/mL) effectively stains lymphatic structures in paraffin-embedded tissues, visualized via HRP-DAB staining .
-
Mouse Models: Used to identify MHC-II/PD-L1 upregulation in peritumoral lymphatic endothelial cells (LECs) in B16F10 tumor-bearing mice .
Western Blot
Regulation by TGF-β
-
TGF-β1, -β2, and -β3 reduce LYVE-1 expression in primary human LECs by 40–60% after 72–100 hours (Western blot analysis) .
| Treatment | Duration | LYVE-1 Reduction | Method |
|---|---|---|---|
| TGF-β1 (30 ng/mL) | 72 hrs | ~55% | Western blot |
| TGF-β2 (30 ng/mL) | 100 hrs | ~60% | Densitometry |
Tumor Microenvironment Studies
-
Peritumoral LECs exhibit elevated PD-L1 and MHC-II compared to naïve LECs in murine melanoma models .
-
LYVE-1 staining combined with MHC-II immunofluorescence reveals spatial immune activation patterns .
Therapeutic Implications
LYVE-1 antibodies are used to study:
-
Immune checkpoint modulation (e.g., PD-L1 dynamics in LECs) .
-
Drug response evaluation (e.g., TGF-β-mediated LYVE-1 suppression) .
Comparative Insights from Related Antibody Research
While LYVE-1 itself is not directly therapeutic, studies on engineered antibodies (e.g., anti-PD-1 armored γδ T cells) demonstrate methodologies relevant to LYVE-1 research:
-
Antibody engineering: Lentiviral constructs for stable expression (e.g., PD-1 antibodies in γδ T cells) .
-
Functional assays: Cytotoxicity and cytokine release profiling .
Technical Considerations
-
Cross-reactivity: Partial reactivity with murine LYVE-1 necessitates validation for interspecies studies .
-
Buffer compatibility: Optimized for Immunoblot Buffer Group 8 and chromogenic IHC protocols .
Ongoing Challenges
Product Specs
Composition: 50% Glycerol, 0.01M PBS, pH 7.4
Target Background
STRING: 6239.F09E8.7a
UniGene: Cel.19676
Q&A
Based on a comprehensive analysis of available research literature and patent filings related to antibody characterization and applications, here is a structured FAQ addressing key research considerations for antibody studies in academic contexts:
Advanced Research Questions
How to resolve contradictory binding data across platforms?
| Discrepancy Type | Resolution Strategy |
|---|---|
| WB+ vs IHC- | Check post-translational modifications |
| Flow+ vs ELISA- | Investigate conformational epitopes |
| Animal vs human models | Perform epitope mapping |
What computational tools predict antibody-antigen interactions?
-
Molecular dynamics simulations for:
How to design bispecific antibodies for T-cell engagement?
| Parameter | Optimal Range |
|---|---|
| CD3 affinity | 10-100 μM |
| Target affinity | ≤10 nM |
| Valency | 1:1 > 2:1 format for reduced toxicity |
Methodological Considerations
7. Standardized protocol for antibody validation:
-
Define purpose-specific validation criteria
-
Establish quantitative metrics (e.g., signal-to-noise ratio ≥5:1)
8. Statistical approaches for binding kinetics analysis:
